|Application ||WB, IHC-P, FC, E|
|Other Accession||Q3UNW5, NP_055368.1|
|Calculated MW||54627 Da|
|Antigen Region||222-251 aa|
|Other Names||Transcription factor CP2-like protein 1, CP2-related transcriptional repressor 1, CRTR-1, Transcription factor LBP-9, TFCP2L1, CRTR1, LBP9|
|Target/Specificity||This TFCP2L1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 222-251 amino acids from the Central region of human TFCP2L1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TFCP2L1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that facilitates establishment and maintenance of pluripotency in embryonic stem cells (ESCs) (PubMed:25215486, PubMed:26906118). With KLF2, acts as the major effector of self-renewal that mediates induction of pluripotency downstream of LIF/STAT3 and Wnt/beta-catenin signaling (By similarity). Required for normal duct development in the salivary gland and kidney (By similarity). Coordinates the development of the kidney collecting ducts intercalated (IC) and principal (PC) cells, which regulate acid-base and salt-water homeostasis, respectively (By similarity). Regulates the expression of IC genes including subunits B1 and D2 of the V-ATPase complex, OXGR1, CA12, SLC4A1, AQP6 and IC-specific transcription factor FOXI1 (By similarity). Regulates also the expression of JAG1 and subsequent notch signaling in the collecting duct (By similarity). JAG1 initiates notch signaling in PCs but inhibits notch signaling in ICs (By similarity). Acts as a transcriptional suppressor that may suppress UBP1-mediated transcriptional activation (By similarity). Modulates the placental expression of CYP11A1 (PubMed:10644752).|
|Tissue Location||Highly expressed in placental JEG-3 cells and very low levels of expression in non-steroidogenic cells. No expression was seen in adrenal NCI-H295A cells or in adrenal tissue.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TFCP2L1is a transcriptional suppressor. It may suppress UBP1-mediated transcriptional activation. Modulates the placental expression of CYP11A1.
To, S., et al. PLoS ONE 5 (7), E11702 (2010) :
Henderson, Y.C., et al. DNA Cell Biol. 27(2):71-79(2008)
Hillier, L.W., et al. Nature 434(7034):724-731(2005)
Huang, N., et al. Mol. Endocrinol. 19(2):409-420(2005)
Rodda, S., et al. J. Biol. Chem. 276(5):3324-3332(2001)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.